This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Field, P. R.
Right arrow Articles by Murphy, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Field, P. R.
Right arrow Articles by Murphy, A. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2002, p. 3526-3529, Vol. 40, No. 9
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.9.3526-3529.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Evaluation of a Novel Commercial Enzyme-Linked Immunosorbent Assay Detecting Coxiella burnetii-Specific Immunoglobulin G for Q Fever Prevaccination Screening and Diagnosis

Peter R. Field,1 Avelina Santiago,1* Sau-Wan Chan,1 Dhara B. Patel,1 David Dickeson,1 Jody L. Mitchell,2 Peter L. Devine,2,{dagger} and Alan M. Murphy3

Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead,1 Viral Diagnostic and Referral Laboratory, North Ryde, New South Wales,3 PanBio Pty Limited, Brisbane, Queensland, Australia2

Received 3 December 2001/ Returned for modification 10 March 2002/ Accepted 20 June 2002

A novel commercially available enzyme-linked immunosorbent assay (ELISA) for prevaccination screening and diagnosis of Q fever (PanBio Coxiella burnetii immunoglobulin G [IgG] ELISA) was compared to the complement fixation test (CFT), and the indirect fluorescent-antibody test (IFAT) was used to resolve discrepant results between the other two tests. A total of 214 serum samples was tested. The ELISA demonstrated a specificity of 96% (46 of 48 samples) and a sensitivity of 71% (95 of 134 samples). Of the six serum pairs showing CFT seroconversion, three pairs showed a corresponding ELISA seroconversion. No cross-reactivity was observed in the ELISA with serum samples from patients with mycoplasma, brucella, and chlamydia infections. One of the 13 patients with leptospirosis demonstrated a positive result in the ELISA but not in the CFT or the IFAT, and Legionella pneumophila serogroup 4 antibody was found in one of the two sera that were false-positive by ELISA. The results presented in this study suggest that the PanBio Q fever IgG ELISA is a specific alternative method for prevaccination testing and an aid for the diagnosis of Q fever. This test is suitable for use as a screening assay, with CFT and/or IFAT used to confirm negative results.

* Corresponding author. Mailing address: CIDMLS, ICPMR, Westmead Hospital, Institute Road, Westmead, New South Wales 2145, Australia. Phone: 61-2-98457748. Fax: 61-2-96335314. E-mail: ninas{at}icpmr.wsahs.nsw.gov.au.

{dagger} Present address: Progen Industries, Darra, Queensland, Australia.

Journal of Clinical Microbiology, September 2002, p. 3526-3529, Vol. 40, No. 9
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.9.3526-3529.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Setiyono, A., Ogawa, M., Cai, Y., Shiga, S., Kishimoto, T., Kurane, I. (2005). New Criteria for Immunofluorescence Assay for Q Fever Diagnosis in Japan. J. Clin. Microbiol. 43: 5555-5559 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»